EN
Examining the Effect of Metformin on Cell Death Mechanisms in Relation to Hippo Signaling in MDA-MB-231 Breast Cancer Cells
Abstract
Breast cancer is one of the most common cancer types in women in the world and our country. Antitumorigenic activity is achieved with various therapeutic drugs by directly suppressing the constantly active PI3K/Akt/mTOR signaling pathway or enabling AMPK activation. AMPK, a positive regulator of autophagy, ensures the induction of autophagy by suppressing the Akt/mTOR pathway. Metformin, an anti-diabetic drug, achieves its anti-tumorigenic effect by activating AMPK. Deregulation of the Hippo signaling pathway is a new therapeutic target because it causes cancer cells to become aggressive and evade cell death mechanisms. The study aims to reveal the effects of metformin treatment on Hippo signaling pathway activity on apoptosis and autophagy, depending on drug treatment in MDA-MB-231 breast cancer cells. Metformin decreased the cell viability through induction of mitochondria membrane potential loss in dose and time dependent manner in MDA-MB-231 cells. The colony forming potential of the MDA-MB-231 cells were suppressed by 10 mM metformin treatment which was induced apoptotic cell death and autophagy by increasing Bim, Bad, Bak and cleavage of caspase 3, 9, PARP and Beclin1, Atg5 and Atg7. Moreover, Hippo signaling related protein levels showed remarkable increase due to metformin treatment. It was shown that metformin treatment increased the activity of the hippo signaling pathway, resulting in the induction of apoptosis and autophagy
Keywords
Supporting Institution
İstanbul Kültür Üniversitesi
Thanks
İstanbul Kültür Üniversitesi Bilimsel Araştırma Projeleri Koordinasyon Birimi
References
- [1] Ferlay J., Colombet M., Soerjomataram I., Mathers C., Parkin DM, Piñeros M. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods, Int J Cancer, 144 (8) (2019) 1941–53.
- [2] IARC. GLOBOCAN : Estimated Number of New Cases from 2020. Int Agency Res Cancer. 247 (22) (2020) 3087–3088.
- [3] Erices R., Cubillos S., Aravena R., Santoro F., Marquez M., Orellana R. Diabetic concentrations of metformin inhibit platelet-mediated ovarian cancer cell progression, Oncotarget, 8 (13) (2017) 20865–20880.
- [4] Wang YW., He SJ., Feng X., Cheng J., Luo YT., Tian L. Metformin: a review of its potential indications, Drug Des Devel Ther., 11 (2017) 2421–2429.
- [5] Vancura A, Bu P, Bhagwat M, Zeng J, Vancurova I. Metformin as an Anticancer Agent, Trends Pharmacol Sci., 39 (10) (2018) 867–878.
- [6] Sabit H., Abdel-Ghany SE., M Said OA., Mostafa MA., El-Zawahry M. Metformin Reshapes the Methylation Profile in Breast and Colorectal Cancer Cells, Asian Pac J Cancer Prev. 19 (10) (2018) 2991–2999.
- [7] Wu L., Zhou B., Oshiro-Rapley N., Li M., Paulo JA., Webster CM., An Ancient, Unified Mechanism for Metformin Growth Inhibition in C. elegans and Cancer, Cell, 167 (7) (2016) 1705-1718.e13.
- [8] Davies G., Lobanova L., Dawicki W., Groot G., Gordon JR., Bowen M. Metformin inhibits the development, and promotes the resensitization, of treatment-resistant breast cancer, PLoS One 12 (12) (2017) e0187191.
Details
Primary Language
English
Subjects
Biochemistry and Cell Biology (Other)
Journal Section
Research Article
Authors
Publication Date
June 30, 2024
Submission Date
November 30, 2023
Acceptance Date
May 30, 2024
Published in Issue
Year 1970 Volume: 45 Number: 2